Patients Stopping Weight-Loss Medications Put On Weight Four Times Faster Than People Using Diet and Exercise

A recent study reveals that individuals who come off blockbuster GLP-1 drugs like Mounjaro or Wegovy may regain reduced body mass much more quickly than those who stop traditional lifestyle programs.

Findings released in a prominent health publication demonstrates that while overweight individuals often shed a large proportion of their total mass while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month once they quit.

"People buying such drugs must be informed of the potential of fast weight regain when the treatment concludes," warns lead investigator Dr. Susan Jebb.

That rate of recovery implies a reversion to original weight in about one and a half years.

Analyzing Treatments

The analysis, which examined 37 of trials involving over 9,000 of patients, contrasted the results of the injectable medications with other pills.

The team point out that people who lose weight through lifestyle changes alone usually have a more gradual creep back—approximately 0.1 kg a month—post-intervention.

The Reason for the Quick Regain

Experts suggest the mechanism of the jabs is key to understanding the amplified regain.

GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.

"Artificially providing the hormone concentrations several times higher than the body's typical production could lead to the system to produce less of its endogenous hormone, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.

"Stopping of this medication leads to hunger is unsuppressed, making binge eating far more likely."

A Lifelong Condition?

Health authorities advise the injections for people with weight-linked health risks, accompanied by prescribed lifestyle changes.

A number of clinicians argue that, considering the high risk of relapse, the therapy might need to be long-term.

This view is supported by pharmaceutical companies, who note that the findings "underscore the persistent character of obesity," akin to managing conditions like hypertension.

Patient Experiences

Users who have discontinued the medication report a sudden resurgence of cravings.

"It was like something that goes on and you become starving," described an individual.

This challenge is compounded if patients have not adopted sustainable lifestyle or habit changes during therapy.

Significant Use

Survey data indicate that a significant number of adults in the UK have tried these injections in the past year, with demand continuing to grow.

• Adoption is more common among females compared to men.
• The 40s and 50s demographic shows the greatest level of interest.
• Many access the medications through private healthcare rather than the NHS.

Finally, researchers caution that while the jabs are powerful tools for weight loss, they are not a permanent fix and maintained weight loss likely depends on ongoing lifestyle management.